| Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist M Iglarz, C Binkert, K Morrison, W Fischli, J Gatfield, A Treiber, T Weller, ... Journal of Pharmacology and Experimental Therapeutics 327 (3), 736-745, 2008 | 444 | 2008 |
| Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction F Amiri, A Virdis, MF Neves, M Iglarz, NG Seidah, RM Touyz, ... Circulation 110 (15), 2233-2240, 2004 | 420 | 2004 |
| Effect of peroxisome proliferator–activated receptor-α and-γ activators on vascular remodeling in endothelin-dependent hypertension M Iglarz, RM Touyz, F Amiri, MF Lavoie, QN Diep, EL Schiffrin Arteriosclerosis, thrombosis, and vascular biology 23 (1), 45-51, 2003 | 270 | 2003 |
| The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propylsulfamide (Macitentan), an Orally Active, Potent Dual … MH Bolli, C Boss, C Binkert, S Buchmann, D Bur, P Hess, M Iglarz, ... Journal of medicinal chemistry 55 (17), 7849-7861, 2012 | 216 | 2012 |
| Involvement of oxidative stress in the profibrotic action of aldosterone: interaction with the renin-angiotensin system M Iglarz, RM Touyz, EC Viel, F Amiri, EL Schiffrin American journal of hypertension 17 (7), 597-603, 2004 | 208 | 2004 |
| Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension EL Schiffrin, F Amiri, K Benkirane, M Iglarz, QN Diep Hypertension 42 (4), 664-668, 2003 | 198 | 2003 |
| Peroxisome proliferator-activated receptor-α and receptor-γ activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension M Iglarz, RM Touyz, EC Viel, P Paradis, F Amiri, QN Diep, EL Schiffrin Hypertension 42 (4), 737-743, 2003 | 187 | 2003 |
| Mechanisms of ET-1-induced endothelial dysfunction M Iglarz, M Clozel Journal of cardiovascular pharmacology 50 (6), 621-628, 2007 | 186 | 2007 |
| Endothelin-2 in ovarian follicle rupture CM Ko, MC Gieske, L Al-Alem, YK Hahn, W Su, MC Gong, M Iglarz, Y Koo Endocrinology 147 (4), 1770-1779, 2006 | 163 | 2006 |
| Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats DH Endemann, RM Touyz, M Iglarz, C Savoia, EL Schiffrin Hypertension 43 (6), 1252-1257, 2004 | 150 | 2004 |
| Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb JS Silvestre, R Tamarat, T Senbonmatsu, T Icchiki, T Ebrahimian, M Iglarz, ... Circulation research 90 (10), 1072-1079, 2002 | 148 | 2002 |
| Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats M Clozel, P Hess, M Rey, M Iglarz, C Binkert, C Qiu Experimental biology and medicine 231 (6), 967-973, 2006 | 134 | 2006 |
| The endothelial-mesenchymal transition in systemic sclerosis is induced by endothelin-1 and transforming growth factor-β and may be blocked by macitentan, a dual endothelin-1 … P Cipriani, P Di Benedetto, P Ruscitti, D Capece, F Zazzeroni, V Liakouli, ... The Journal of rheumatology 42 (10), 1808-1816, 2015 | 104 | 2015 |
| Role of endothelin-1 in hypertension M Iglarz, EL Schiffrin Current Hypertension Reports 5 (2), 144-148, 2003 | 104 | 2003 |
| Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase–deficient mice A Virdis, M Iglarz, MF Neves, F Amiri, RM Touyz, R Rozen, EL Schiffrin Arteriosclerosis, thrombosis, and vascular biology 23 (8), 1352-1357, 2003 | 102 | 2003 |
| At the heart of tissue: endothelin system and end-organ damage M Iglarz, M Clozel Clinical science 119 (11), 453-463, 2010 | 83 | 2010 |
| Dual endothelin-A/endothelin-B receptor blockade and cardiac remodeling in heart failure with preserved ejection fraction M Valero-Munoz, S Li, RM Wilson, B Boldbaatar, M Iglarz, F Sam Circulation: Heart Failure 9 (11), e003381, 2016 | 80 | 2016 |
| Chronic blockade of endothelin receptors improves ischemia-induced angiogenesis in rat hindlimbs through activation of vascular endothelial growth factor–NO pathway M Iglarz, JS Silvestre, M Duriez, D Henrion, BI Lévy Arteriosclerosis, thrombosis, and vascular biology 21 (10), 1598-1603, 2001 | 73 | 2001 |
| Endothelin ETA receptor blockade, by activating ETB receptors, increases vascular permeability and induces exaggerated fluid retention M Vercauteren, F Trensz, A Pasquali, C Cattaneo, DS Strasser, P Hess, ... Journal of Pharmacology and Experimental Therapeutics 361 (2), 322-333, 2017 | 66 | 2017 |
| Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis D Kosanovic, H Luitel, BK Dahal, T Cornitescu, W Janssen, AHJ Danser, ... European Respiratory Journal 46 (4), 1084-1094, 2015 | 62 | 2015 |
Ernesto L. SchiffrinProfessor, Department of Medicine, McGill University在 mcgill.ca 的电子邮件经过验证
